Table 1.
Patients’ characteristics
| Group | A (%) n = 20 | B (%) n = 24 | C (%) n = 21 | Control (%) n = 21 | P |
|---|---|---|---|---|---|
| Age (Range) | 33 (26–38) | 35 (27–40) | 36 (26–39) | 35 (26–40) | 0.98 |
| FIGO staging | |||||
| Ib1 | 4 (20.0) | 8 (33.3) | 6 (28.6) | 5 (23.8) | 0.77 |
| Ib2 | 6 (30.0) | 9 (37.5) | 7 (33.3) | 6 (28.6) | 0.89 |
| IIa1 | 5 (25.0) | 4 (16.7) | 4 (19.0) | 5 (23.8) | 0.89 |
| IIa2 | 5 (25.0) | 3 (12.5) | 4 (19.0) | 5 (23.8) | 0.71 |
| Histological types | |||||
| Squamous cell carcinoma | 15 (75.0) | 18 (75.0) | 14 (66.7) | 15 (71.4) | 0.91 |
| Adenocarcinoma | 2 (10.0) | 4 (16.7) | 6 (28.6) | 4 (19.0) | 0.49 |
| Adenosquamous carcinoma | 3 (15.0) | 2 (8.3) | 1 (4.8) | 2 (9.5) | 0.72 |
| Surgical procedures | |||||
| One ovarian transposition | 3 (15.0) | 4 (16.7) | 3 (14.3) | 3 (14.3) | 0.99 |
| Ovarian transposition | 17 (85.0) | 20 (83.3) | 18 (85.7) | 18 (85.7) | 0.99 |
| Concurrent chemotherapy | 16 (80.0) | 19 (79.0) | 17 (81.0) | 0 (0.0) | 0.99 |
| Pelvic radiation dose | 4500–5000 cGy | 4500–5000 cGy | 4500–5000 cGy | 4500–5000 cGy | |
| Ovary limit dose | No | No | V10 < 20% | No | |
| Brachytherapy | 12 (60.0) | 13 (54.2) | 11 (52.4) | 12 (57.1) | 0.93 |
There is no statistically significant difference at age and clinical staging among four groups (P < 0.05). Because the chemotherapy was not used in control group, we only compared the experimental group combined with chemotherapy.